# Non-Ablative Allo HSCT For Hematologic Malignancies or SAA

> **NCT00006379** · PHASE2 · COMPLETED · sponsor: **Case Comprehensive Cancer Center** · enrollment: 58 (actual)

## Conditions studied

- Chronic Myeloproliferative Disorders
- Leukemia
- Lymphoma
- Multiple Myeloma and Plasma Cell Neoplasm
- Myelodysplastic Syndromes
- Myelodysplastic/Myeloproliferative Diseases
- Precancerous/Nonmalignant Condition
- Small Intestine Cancer

## Interventions

- **BIOLOGICAL:** anti-thymocyte globulin
- **BIOLOGICAL:** graft-versus-tumor induction therapy
- **DRUG:** cyclophosphamide
- **DRUG:** fludarabine phosphate
- **PROCEDURE:** peripheral blood stem cell transplantation

## Key facts

- **NCT ID:** NCT00006379
- **Lead sponsor:** Case Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-06
- **Primary completion:** 2004-01
- **Final completion:** 2011-10
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2011-12-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00006379

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00006379, "Non-Ablative Allo HSCT For Hematologic Malignancies or SAA". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00006379. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*